Gene Review:
CPB2 - carboxypeptidase B2 (plasma)
Homo sapiens
Synonyms:
CPU, Carboxypeptidase B2, Carboxypeptidase U, PCPB, Plasma carboxypeptidase B, ...
Weltermann,
Glu,
Antovic,
Gresele,
Booth,
Eichinger,
Griffin,
Bruni,
Hambsch,
Nagashima,
Rijken,
Demirkan,
Nishimura,
Schneider,
Ozcan,
Colucci,
Hackeng,
Hendriks,
Tárnok,
Yüksel,
Yun,
Goossens,
Schatteman,
Schönauer,
Semeraro,
Morser,
Puccetti,
Schlykow,
Hirschl,
Sakharov,
Bova,
Cercignani,
Patterson,
Hamsten,
Mutch,
Marx,
Wang,
Bialonczyk,
Silveira,
Pearl,
Scharpé,
Binetti,
Plow,
Dawson,
Pastorelli,
Bouma,
Minar,
Undar,
Clerici,
Alakavuklar,
Myles,
Morelli,
Blombäck,
Moor,
Moore,
Strömqvist,
Rössler,
Branca,
Meijers,
Kyrle,
Palazzuoli,
Leung,
Quehenberger,
Schneider,
Bocsi,
Auteri,
Pasqui,
- Acute phase mediators modulate thrombin-activable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells. Boffa, M.B., Hamill, J.D., Maret, D., Brown, D., Scott, M.L., Nesheim, M.E., Koschinsky, M.L. J. Biol. Chem. (2003)
- Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B). Boffa, M.B., Reid, T.S., Joo, E., Nesheim, M.E., Koschinsky, M.L. Biochemistry (1999)
- Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation. Antovic, J.P., Blombäck, M. Thromb. Res. (2002)
- Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. Mutch, N.J., Moore, N.R., Wang, E., Booth, N.A. J. Thromb. Haemost. (2003)
- Dyslipidemias and fibrinolysis. Puccetti, L., Bruni, F., Pasqui, A.L., Pastorelli, M., Bova, G., Cercignani, M., Palazzuoli, A., Auteri, A. Italian heart journal : official journal of the Italian Federation of Cardiology. (2002)
- Performance analysis of a medical record exchanges model. Huang, E.W., Liou, D.M. IEEE transactions on information technology in biomedicine : a publication of the IEEE Engineering in Medicine and Biology Society (2007)
- Plasma carboxypeptidases as regulators of the plasminogen system. Redlitz, A., Tan, A.K., Eaton, D.L., Plow, E.F. J. Clin. Invest. (1995)
- Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study. Frère, C., Tregouet, D.A., Morange, P.E., Saut, N., Kouassi, D., Juhan-Vague, I., Tiret, L., Alessi, M.C. Blood (2006)
- Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Eichinger, S., Schönauer, V., Weltermann, A., Minar, E., Bialonczyk, C., Hirschl, M., Schneider, B., Quehenberger, P., Kyrle, P.A. Blood (2004)
- Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. Myles, T., Nishimura, T., Yun, T.H., Nagashima, M., Morser, J., Patterson, A.J., Pearl, R.G., Leung, L.L. J. Biol. Chem. (2003)
- The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1. Ozeren, M., Karahan, S.C., Ozgur, M., Eminagaoglu, S., Unsal, M., Baytan, S., Bozkaya, H. Acta obstetricia et gynecologica Scandinavica. (2005)
- The effect of anthracycline-based (epirubicin) adjuvant chemotherapy on plasma TAFI and PAI-1 levels in operable breast cancer. Demirkan, B., Ozcan, M.A., Glu, A.A., Yüksel, F., Undar, B., Alakavuklar, M. Clin. Appl. Thromb. Hemost. (2006)
- Elevated Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Antigen Levels in Overt and Subclinical Hypothyroid Patients Were Reduced by Levothyroxine Replacement. Akinci, B., Comlekci, A., Ali Ozcan, M., Demir, T., Yener, S., Demirkan, F., Yuksel, F., Yesil, S. Endocr. J. (2007)
- The stage-regulated expression of Leishmania mexicana CPB cysteine proteases is mediated by an intercistronic sequence element. Brooks, D.R., Denise, H., Westrop, G.D., Coombs, G.H., Mottram, J.C. J. Biol. Chem. (2001)
- The gene encoding human plasma carboxypeptidase B (CPB2) resides on chromosome 13. Tsai, S.P., Drayna, D. Genomics (1992)
- Association of a single nucleotide polymorphism in CPB2 encoding the thrombin-activable fibrinolysis inhibitor (TAF1) with blood pressure. Koschinsky, M.L., Boffa, M.B., Nesheim, M.E., Zinman, B., Hanley, A.J., Harris, S.B., Cao, H., Hegele, R.A. Clin. Genet. (2001)
- Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor. Bajzar, L., Nesheim, M., Morser, J., Tracy, P.B. J. Biol. Chem. (1998)
- Thrombin-activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis. Lau, H.K., Segev, A., Hegele, R.A., Sparkes, J.D., Teitel, J.M., Chisholm, R.J., Strauss, B.H. Thromb. Haemost. (2003)
- Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. Aubert, H., Frère, C., Aillaud, M.F., Morange, P.E., Juhan-Vague, I., Alessi, M.C. J. Thromb. Haemost. (2003)
- Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Silveira, A., Schatteman, K., Goossens, F., Moor, E., Scharpé, S., Strömqvist, M., Hendriks, D., Hamsten, A. Thromb. Haemost. (2000)
- The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex. Wu, C., Kim, P.Y., Manuel, R., Seto, M., Whitlow, M., Nagashima, M., Morser, J., Gils, A., Declerck, P., Nesheim, M.E. J. Biol. Chem. (2009)
- Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and down regulation of TAFI activation. Mosnier, L.O., Elisen, M.G., Bouma, B.N., Meijers, J.C. Thromb. Haemost. (2001)
- On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. Sakharov, D.V., Plow, E.F., Rijken, D.C. J. Biol. Chem. (1997)
- Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C. Kokame, K., Zheng, X., Sadler, J.E. J. Biol. Chem. (1998)
- Thrombin activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy. Mousa, H.A., Downey, C., Alfirevic, Z., Toh, C.H. Thromb. Haemost. (2004)
- Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism. Leurs, J., Nerme, V., Sim, Y., Hendriks, D. J. Thromb. Haemost. (2004)
- Low degree of activation of circulating neutrophils determined by flow cytometry during cardiac surgery with cardiopulmonary bypass. Tárnok, A., Bocsi, J., Rössler, H., Schlykow, V., Schneider, P., Hambsch, J. Cytometry. (2001)
- Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. Marx, P.F., Hackeng, T.M., Dawson, P.E., Griffin, J.H., Meijers, J.C., Bouma, B.N. J. Biol. Chem. (2000)
- Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Colucci, M., Binetti, B.M., Branca, M.G., Clerici, C., Morelli, A., Semeraro, N., Gresele, P. Hepatology (2003)